NovaBridge Biosciences
Hiteck licensed its experimental eye drop, HT006.2.2, to Visara for neurotrophic keratitis treatment outside Greater China. In a Phase 1b study, 50% of high-dose subjects achieved complete corneal healing after 8 weeks. Visara, a subsidiary of NovaBridge Biosciences (NBP), will develop and commercialize the therapy.
NovaBridge Biosciences (NBP) will present updated Phase 1b trial data for givastomig at ESMO Congress 2026. The study evaluates givastomig in combination with nivolumab and chemotherapy for advanced gastroesophageal adenocarcinoma. The FDA has granted Fast Track Designation to givastomig for this indication.
NovaBridge Biosciences (NBP) reported a wider H1 2026 net loss of $37.9M ($0.14 per share) vs. $8.7M ($0.05) a year ago. R&D and admin expenses rose, with cash reserves at $215.9M. The company advanced givastomig (Phase 3 interim data expected 2028) and VIS-101 (Phase 2b study planned H2 2026). NBP stock closed at $1.98, up 4.76%.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning NBP (NovaBridge Biosciences). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent NBP coverage spans financial news, earnings and technology.
In the last 30 days, NBP insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($6K). The most active reporter was Dennis Phillip Andrew, Chief Medical Officer, with 1 filing.
Positive Phase 1b data may boost investor sentiment for NBP.
Conference poster data can shift biotech sentiment and near-term positioning, but the article provides no new efficacy or safety numbers.
The earnings miss and cash runway raise short‑term risk, while the strong early trial data could boost long‑term upside.
Positive early‑stage trial data and a strong cash position could lift the stock, while upcoming Phase 3 initiation adds upside potential.
Near-term governance continuity reduces immediate leadership-change risk, but the short extension implies uncertainty about the eventual permanent CEO timeline.
AlphAI scores every news story that mentions NBP with an AI model for sentiment and relevance, and aggregates insider trades from NovaBridge Biosciences's SEC EDGAR Form 4 filings. Figures refresh continuously.
Hiteck licensed its experimental eye drop, HT006.2.2, to Visara for neurotrophic keratitis treatment outside Greater China. In a Phase 1b study, 50% of high-dose subjects achieved complete corneal healing after 8 weeks. Visara, a subsidiary of NovaBridge Biosciences (NBP), will develop and commercialize the therapy.
2 min readNovaBridge Biosciences (NBP) will present updated Phase 1b trial data for givastomig at ESMO Congress 2026. The study evaluates givastomig in combination with nivolumab and chemotherapy for advanced gastroesophageal adenocarcinoma. The FDA has granted Fast Track Designation to givastomig for this indication.
3 min readNovaBridge Biosciences (NBP) reported a wider H1 2026 net loss of $37.9M ($0.14 per share) vs. $8.7M ($0.05) a year ago. R&D and admin expenses rose, with cash reserves at $215.9M. The company advanced givastomig (Phase 3 interim data expected 2028) and VIS-101 (Phase 2b study planned H2 2026). NBP stock closed at $1.98, up 4.76%.
3 min readNovaBridge Biosciences (NBP) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution • Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholders • Appoi
2 min readPakistan’s Finance Division notified that Rehmat Ali Hasnie’s term as President and CEO of National Bank of Pakistan (NBP) is extended by 14 days, effective Aug. 7, 2026, until a successor takes office or the two weeks end, under the Banks (Nationalization) Act, 1974. NBP said the extension was communicated to Pakistan Stock Exchange TRE certificate holders.
3 min readPakistan’s central bank, the State Bank of Pakistan (SBP), appointed 10 Primary Dealers and two Special Purpose Primary Dealers for fiscal year 2026-27. UBL, NBP and Bank Alfalah were top performers in FY2025-26, per an SBP notification. PDs support auctions, distribution and secondary trading of government securities as the government relies on domestic borrowing.
3 min readXu Cong Claire (SVP, Clinical Development) sold 3,494 shares of NovaBridge Biosciences (NBP) at $3.94 on 2026-06-01.
2 min readNovaBridge Biosciences (Nasdaq: NBP) said senior management will present at the 2026 Jefferies Global Healthcare Conference June 2–4, 2026, with a company presentation scheduled for June 4 at 3:10 PM ET. The webcast will be available on its investor relations site for 90 days, the company said.
2 min readROCKVILLE, Md., Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- NovaBridge Biosciences ( Nasdaq: NBP ) ( NovaBridge or the Company ) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that its subsidiary Visara, Inc. ( Visara ) has appointed ...
2 min readCadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program
3 min read
